Key result
TEER safely reduces severe symptomatic TR despite lacking randomized controlled data.
Why the study?
Tricuspid regurgitation is common and associated with significant morbidity and mortality, with evolving transcatheter treatment technologies alongside uncertainties regarding procedural timing and clinical benefit.
This review summarizes the current state of transcatheter edge-to-edge repair for tricuspid regurgitation, highlighting its effectiveness in TR reduction alongside ongoing uncertainties about optimal timing and clinical benefit.
May warrant consideration in selected refractory cases; leaves open confirmation of clinical benefit in randomized trials.
Tricuspid regurgitation (TR) is a common disease associated with significant morbidities and mortality. In this review, the new grading scheme of TR, the tricuspid valve anatomy and also the different TR mechanisms are summarised. Recently, there have been many evolving technologies to treat TR, and transcatheter edge-to-edge repair is one of the most well-established techniques. Transcatheter edge-to-edge repair is shown to be effective in TR reduction. With increasing clinical experience, a number of echocardiographic predictors of optimal TR reduction have been identified, and a standardised transoesophageal echocardiogram protocol and also different techniques to improve the procedural success are presented. Finally, the uncertainties on the optimal timing of TR intervention and on the clinical benefit of transcatheter edge-to-edge repair are also addressed.
No takes yet. Share an insight, caveat, or question.
So et al. (2023) conducted a review in Tricuspid regurgitation. Transcatheter edge-to-edge repair (TEER) was evaluated. Transcatheter edge-to-edge repair is a safe and effective interventional therapy for reducing severe symptomatic tricuspid regurgitation, though randomized controlled data are currently lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: